Crizotinib acetate
| Code | Size | Price |
|---|
| TAR-T1661L-5mg | 5mg | £930.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T1661L-50mg | 50mg | £1,821.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T1661L-100mg | 100mg | £2,319.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Crizotinib, an orally bioavailable agent, belongs to the class of c-met/hepatocyte growth factor receptor (HGFR) tyrosine kinase inhibitors with potential antineoplastic activity.
CAS:
877399-53-6
Formula:
C23H26Cl2FN5O3
Molecular Weight:
510.39
Purity:
0.98
SMILES:
CC(O)=O.C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl
References
1. Theilen TM, Soerensen J, Bochennek K, Becker M, Schwabe D, Rolle U, Klingebiel T, Lehrnbecher T. Crizotinib in ALK(+) inflammatory myofibroblastic tumors-Current experience and future perspectives. Pediatr Blood Cancer. 2017 Dec 29. doi: 10.1002/pbc.26920. [Epub ahead of print] Review. PubMed PMID: 29286567.
2. Sgambato A, Casaluce F, Maione P, Gridelli C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6. Review. PubMed PMID: 29187012.
3. Manicone M, Scaini MC, Rodriquenz MG, Facchinetti A, Tartarone A, Aieta M, Zamarchi R, Rossi E. Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. J Thorac Dis. 2017 Oct;9(Suppl 13):S1391-S1396. doi: 10.21037/jtd.2017.08.151. Review. PubMed PMID: 29184678; PubMed Central PMCID: PMC5676101.
4. Pellegrino B, Facchinetti F, Bordi P, Silva M, Gnetti L, Tiseo M. Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature. Clin Lung Cancer. 2017 Oct 28. pii: S1525-7304(17)30302-9. doi: 10.1016/j.cllc.2017.10.008. [Epub ahead of print] Review. PubMed PMID: 29174221.